<div><p>(A–C): Hematoxylin and eosin stains (magnification 500×) of BM (A), spleen (B), and liver (C) from representative polycythemic recipients of JAK2 V617F-transduced BM.</p> <p>In the spleen, a lymphoid follicle (f) and an area of erythroid hyperplasia (e) are indicated.</p> <p>The same tissues from recipients of JAK2 WT-transduced BM showed no pathological changes compared with normal controls (data not shown).</p> <p>(D) Wright-Giemsa stains (top panels) and acetylcholinesterase stains (bottom panels) of purified megakaryocytes from recipients of JAK2 V617F-transduced BM (right panels) or normal control mice (left panels).</p> <p>Note the preponderance of small m...
The JAK2 V617F mutation is found in most patients with a myeloproliferative neoplasm and is sufficie...
The majority of patients with myeloproliferative neoplasms (MPNs) carry a somatic JAK2-V617F mutatio...
<p>(A) The number of population doublings (PD) in each passage was calculated using the following eq...
<div><p>(A–C): Hematocrit (A), blood hemoglobin (B), and reticulocyte counts (C) from normal (–) B6 ...
<div><p>(A) Peripheral blood leukocyte counts for the three cohorts in Balb/c and B6 backgrounds as ...
<div><p>(A) Box-style plots of hematocrit (red squares, left axis) and reticulocyte counts (blue tri...
<p>Histology of MPLW515L-transduced and MPLWT-transduced Balb/C mice showing images of peripheral bl...
A somatic activating mutation (V617F) in the JAK2 tyrosine kinase was recently discovered in the maj...
A somatic activating mutation (V617F) in the JAK2 tyrosine kinase was recently discovered in the maj...
An acquired JAK2 V617F mutation is found in most patients with polycythemia vera (PV), and about hal...
We evaluated the NOD/SCID engraftment of CD34 + cells from polycythemia vera (PV) and secondary poly...
found in patients with myeloprolifera-tive disorders (MPDs), including most with polycythemia vera (...
We report a Jak2V617F knockin mouse myeloproliferative neoplasm (MPN) model resembling human polycyt...
<p>(A) Kaplan-Meier survival curves for control (n = 17) and age-matched Jak2 cKO mice (n = 34). (B)...
SummaryPolycythemia Vera (PV) is a myeloproliferative disorder (MPD) that is commonly characterized ...
The JAK2 V617F mutation is found in most patients with a myeloproliferative neoplasm and is sufficie...
The majority of patients with myeloproliferative neoplasms (MPNs) carry a somatic JAK2-V617F mutatio...
<p>(A) The number of population doublings (PD) in each passage was calculated using the following eq...
<div><p>(A–C): Hematocrit (A), blood hemoglobin (B), and reticulocyte counts (C) from normal (–) B6 ...
<div><p>(A) Peripheral blood leukocyte counts for the three cohorts in Balb/c and B6 backgrounds as ...
<div><p>(A) Box-style plots of hematocrit (red squares, left axis) and reticulocyte counts (blue tri...
<p>Histology of MPLW515L-transduced and MPLWT-transduced Balb/C mice showing images of peripheral bl...
A somatic activating mutation (V617F) in the JAK2 tyrosine kinase was recently discovered in the maj...
A somatic activating mutation (V617F) in the JAK2 tyrosine kinase was recently discovered in the maj...
An acquired JAK2 V617F mutation is found in most patients with polycythemia vera (PV), and about hal...
We evaluated the NOD/SCID engraftment of CD34 + cells from polycythemia vera (PV) and secondary poly...
found in patients with myeloprolifera-tive disorders (MPDs), including most with polycythemia vera (...
We report a Jak2V617F knockin mouse myeloproliferative neoplasm (MPN) model resembling human polycyt...
<p>(A) Kaplan-Meier survival curves for control (n = 17) and age-matched Jak2 cKO mice (n = 34). (B)...
SummaryPolycythemia Vera (PV) is a myeloproliferative disorder (MPD) that is commonly characterized ...
The JAK2 V617F mutation is found in most patients with a myeloproliferative neoplasm and is sufficie...
The majority of patients with myeloproliferative neoplasms (MPNs) carry a somatic JAK2-V617F mutatio...
<p>(A) The number of population doublings (PD) in each passage was calculated using the following eq...